Carvykti ema marketing authorisation date?

What is Carvykti’s marketing authorisation date?

Carvykti (ciltacabtagene autoleucel) received its marketing authorisation in the European Union on 27 September 2024. [1]

Why do dates sometimes differ between regions?

Marketing authorisation dates can differ by country or region because regulators review and approve medicines on separate timelines. If you mean a specific market (EU, UK, US, etc.), the authorisation date may not match the EU date above. [1]

Where can I verify the official date?

The authorisation date is published in the EU’s official medicine product information for Carvykti. [1]

Sources

1. EMA – Carvykti (ciltacabtagene autoleucel): EPAR product information (marketing authorisation date)